An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00240838|
Recruitment Status : Completed
First Posted : October 18, 2005
Last Update Posted : June 29, 2011
|Condition or disease||Intervention/treatment||Phase|
|Pain||Drug: acetaminophen extended release caplets||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||483 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-Blind Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.|
|Study Start Date :||May 2003|
|Actual Study Completion Date :||June 2003|
- Average change in muscle soreness from baseline for both morning and evening assessments.
- Average change in muscle soreness from baseline for morning assessments; Average change in muscle soreness from baseline for evening assessments; Average ratings of interference with 1) sleep; 2) morning activity; 3) ability to go for a run
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00240838
|Study Director:||McNeil Consumer & Specialty Pharmaceuticals, a Division of Mc Neil-PPC, Inc. Clinical Trial||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|